Mannkind (MNKD) Net Income (2010 - 2026)
Mannkind (MNKD) posted quarterly Net Income of -$16.6 million for Q1 2026, down 226.3% year-over-year from $13.2 million in Q1 2025, and down 4.21% quarter-over-quarter from -$15.9 million in Q4 2025.
Mannkind (MNKD) Net Income (2010 - 2026) Analysis & Trends
Mannkind (MNKD) has reported Net Income for 17 consecutive years, with -$16.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Income fell 226.3% year-over-year to -$16.6 million; the TTM figure through Mar 2026 stood at -$23.9 million (down 179.47% YoY), while the FY2025 annual figure was $5.9 million, down 78.75% from the prior year.
- Net Income eased to -$16.6 million in Q1 2026 per MNKD's latest filing, from -$15.9 million in the prior quarter.
- Across five years, Net Income topped out at $13.2 million in Q1 2025 and bottomed at -$29.0 million in Q2 2022.
- Historically, Net Income has averaged -$4.9 million across 5 years, with a median of -$2.0 million in 2024.
- Annual changes were most pronounced in 2024 — Net Income surged 571.12% — and 2025, when it tumbled 315.08%.
- Mannkind's Net Income stood at -$17.9 million in 2022, then surged by 107.84% to $1.4 million in 2023, then jumped by 427.01% to $7.4 million in 2024, then sank by 315.08% to -$15.9 million in 2025, then dropped by 4.21% to -$16.6 million in 2026.
- Business Quant data shows MNKD's Net Income at -$16.6 million in Q1 2026, -$15.9 million in Q4 2025, and $8.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Mannkind | 1.19 Bn | 1.08 Bn | 94.97 Mn | -19.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -19.03 Mn |
| Mar 31, 2026 | -16.62 Mn |
| Dec 31, 2025 | -15.95 Mn |
| Sep 30, 2025 | 7.98 Mn |
| Jun 30, 2025 | 640,000.00 |
| Mar 31, 2025 | 13.16 Mn |
| Dec 31, 2024 | 7.42 Mn |
| Sep 30, 2024 | 11.55 Mn |
| Jun 30, 2024 | -1.99 Mn |
| Mar 31, 2024 | 10.63 Mn |
| Dec 31, 2023 | 1.41 Mn |
| Sep 30, 2023 | 1.72 Mn |
| Jun 30, 2023 | -5.27 Mn |
| Mar 31, 2023 | -9.80 Mn |
| Dec 31, 2022 | -17.95 Mn |
| Sep 30, 2022 | -14.43 Mn |
| Jun 30, 2022 | -29.02 Mn |
| Mar 31, 2022 | -26.00 Mn |
| Dec 31, 2021 | -28.06 Mn |
| Sep 30, 2021 | -4.43 Mn |